Name /GNT Biotech & Medicals Corporation
Address /Rm. WR-06, 17F., No.3, Park St., Nangang Dist., Taipei 115, Taiwan
Name /Ye-Su Chao
Title /Vice President
Telephone /(Work)886-2-7722-0388 ext. 101
GNT Biotech and Medicals Corporation (GNTbm) focuses on innovative drug research and development for the treatment of advanced cancer, in the field of epigenetics. GNTbm has devoted to develop new treatment with novel anti-cancer mechanism, better safety and better efficacy to meet the clinical unmet needs of patients with advanced and refractory cancers.
The new drug pipelines ranging from epigenetic modulators, combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a continuously developing progress.
GNTbm’s mission is to become an innovative developer in the field of cancer epigenetics. The application of our new drugs in cancer immunotherapy is dedicated to improve and optimize the therapeutic benefits and quality of life of patients, and give patients with advanced cancers a chance to achieve clinical cure.
The main core technologies, including the new drug combination platform for tumor microenvironment regulation, the epigenetic immunomodulation platform and the technology platform of proteolysis target protein degradation drug (HPTC, HDACs Proteolysis Targeting Chimera), are applied for new drug development of cancer immunotherapy. The novel and effective anti-cancer mechanisms based on the design and combinatorial strategy provided through these platforms can effectively improve the therapeutic benefits of treatment for patients with advanced cancer.
Since its establishment GNTbm has been interested in the development of a new-generation epigenetic modulator for cancer treatment, and has partnered with Chipscreen Biosciences, a well-known Chinese new drug company, to develop Chidamide/Tucidinostat for peripheral T cell lymphoma, advanced breast cancer, and other cancer indications. GNTbm-CC-01 is the first new drug combination of tumor microenvironment regulator developed by GNTbm. The drug combination consists of a novel epigenetic modulator Chidamide and a generic drug C. GNTbm-CC-02 has been developed through new formulation of GNTbm-CC-01. It possesses better PK profile and anti-cancer efficacy than GNTbm-CC-01. GNTbm-XX is an epigenetic immunomodulatory agents with novel structure, possessing oral property and excellent immune-regulating activity
GNTbm is devoted to develop new drugs with the goal of fulfilling clinical benefits for patients with advanced or refractory cancers.
Name /Pei- Ching Hsu